Vyv C. Salisbury
A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia
Salisbury, Vyv C.; Hill, Phil J.; Angell, Johanna E.; Ruddock, Mark W.; Martin, Ashley D.; Alloush, Habib M.; Anderson, Elizabeth; Lamont, John; Smith, M. Ann; Smith, J. Graham; Mehta, Priyanka
Authors
Phil J. Hill
Johanna E. Angell
Mark W. Ruddock
Ashley D. Martin
Habib M. Alloush
Elizabeth Anderson Elizabeth3.Anderson@uwe.ac.uk
Senior Lecturer in Haematology
John Lamont
M. Ann Smith
J. Graham Smith
Priyanka Mehta
Abstract
BACKGROUND: The nucleoside analog cytarabine (Ara-C [cytosine arabinoside]) is the key agent for treating acute myeloid leukemia (AML); however, up to 30% of patients fail to respond to treatment. Screening of patient blood samples to determine drug response before commencement of treatment is needed. This project aimed to construct and evaluate a self-bioluminescent reporter strain of Escherichia coli for use as an Ara-C biosensor and to design an in vitro assay to predict Ara-C response in clinical samples. METHODS: Weused transposition mutagenesis to create a cytidine deaminase (cdd)-deficient mutant of E. coli MG1655 that responded to Ara-C. The strain was transformed with the luxCDABE operon and used as a whole-cell biosensor for development an 8-h assay to determine Ara-C uptake and phosphorylation by leukemic cells. RESULTS: Intracellular concentrations of 0.025 μmol/L phosphorylated Ara-C were detected by significantly increased light output (P < 0.05) from the bacterial biosensor. Results using AML cell lines with known response to Ara-C showed close correlation between the 8-h assay and a 3-day cytotoxicity test for Ara-C cell killing. In retrospective tests with 24 clinical samples of bone marrow or peripheral blood, the biosensor-based assay predicted leukemic cell response to Ara-C within 8 h. CONCLUSIONS: The biosensor-based assay may offer a predictor for evaluating the sensitivity of leukemic cells to Ara-C before patients undergo chemotherapy and allow customized treatment of drug-sensitive patients with reduced Ara-C dose levels. The 8-h assay monitors intracellular Ara-CTP (cytosine arabinoside triphosphate) levels and, if fully validated, may be suitable for use in clinical settings. © 2010 American Association for Clinical Chemistry.
Journal Article Type | Article |
---|---|
Publication Date | Dec 1, 2010 |
Deposit Date | Jun 13, 2011 |
Publicly Available Date | Feb 10, 2016 |
Journal | Clinical Chemistry |
Print ISSN | 0009-9147 |
Electronic ISSN | 1530-8561 |
Publisher | American Association for Clinical Chemistry |
Peer Reviewed | Peer Reviewed |
Volume | 56 |
Issue | 12 |
Pages | 1862-1870 |
DOI | https://doi.org/10.1373/clinchem.2010.145581 |
Keywords | biolumuinescent, microbial, biosensor, in vitro, pretreatment, cytarabine, Leukemia |
Public URL | https://uwe-repository.worktribe.com/output/972940 |
Publisher URL | http://dx.doi.org/10.1373/clinchem.2010.145581 |
Contract Date | Feb 10, 2016 |
Files
14920.pdf
(1.2 Mb)
PDF
You might also like
Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease
(2019)
Presentation / Conference Contribution
Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML).
(2019)
Presentation / Conference Contribution
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search